skip to content
Fidia | Homepage
About us
Our milestones
Our culture
Financial and results
Governance
Where we are
Contacts
Joint Care
Skin Care
Specialty Care
Product portfolio
Hyaluronic acid
Research and development
Manufacturing capability
Fully integrated company
Quality management system
Sites
Working in Fidia
Evolving with Fidia

About us

Our Group is an Italian multinational company, established in 1946, with a vocation to create solutions to meet new challenges in health and improve quality of life for people.
scroll down

The strength of insight

We have understood the potential of hyaluronic acid since the 1950s and today we are one of the leading global players in the manufacture of hyaluronic acid-based products. Full control of the supply chain, from research to marketing, sets us apart and for this reason we define ourselves as a fully integrated company.

GLOBAL EMPLOYEES
+1,500
REVENUES IN 2022
412.1 € millions
“

It is always the people who make the difference.
At Fidia we strive every day to improve and evolve.

”

We are constantly evolving

We are a dynamic company and we open up new pathways in international markets, launch new products, and experiment with new approaches.

OUR FIGURES BY FOCUS AREA (€ Millions, 2022)

153,8670866 € Millions
JOINT CARE
82,15611914 € Millions
EYE CARE
47,53698889 € Millions
SKIN CARE
34,32201781 € Millions
CORTICOSTEROIDS
5,14874152 € Millions
ACTIVE SUBSTANCES
89,042855810495 € Millions
OTHER

Our Group grows stronger

We are constantly evolving, including through important international acquisitions.

2023
Unipharm Polska

Fidia acquired some eye care products and a Vitamin D-based nutritional supplement along with a branch of the Polish affiliate of Unipharm, privately owned pharmaceutical company headquartered in the U.S. specializing in the development and marketing of over-the-counter (OTC) drugs and nutritional products.

2021
Strengthening our position in anti-inflammatory drugs

We signed an agreement for the acquisition of a large integrated portfolio of anti-inflammatory drugs commercialized in numerous international markets, thus strengthening Fidia’s presence in them.

2019
Strengthening our position in ophthalmology

We acquired three new ophthalmic products in the Spanish market from Novartis Farma, Spain, a Spanish subsidiary of the Novartis Pharma AG group of companies, Basel. This move is part of a project to strengthen the presence of Fidia in the national and international ophthalmic market, which began in 2017 with the acquisition of Sooft Italia.

2018
Soluciones Bioregenerativas SL

A company working in the sector of regenerative medicine within the field of osteoarticular health, aesthetics, dermatology and veterinary medicine, also thanks to the use of PRP (platelet-rich plasma).

2017
Sooft Italia S.p.A.

A leading player in the Italian ophthalmic market, with a complete range of over 100 products for eye health: medicines, supplements and medical devices.

2016
Biofarmitalia

Company specializes in novel technologies for cosmetic and pharmaceutical applications. Now an integral part of Fidia following a merger by incorporation in December 2019.
“

For us, innovation means studying, discovering, creating new solutions, continuously improving existing products.

”

Innovation is the gateway to the future

Also thanks to our well-established body of patents involving hyaluronic acid, our research never stops.

CLINICAL STUDIES ON HYALURONIC ACID
+310
PATENTS
+1,300

Media room

Press materials, images and videos of our company and institutional information.

Find out more